小柯机器人

广东省人民医院吴一龙团队完成贝伐珠单抗加厄洛替尼治疗未经治疗、EGFR突变的晚期非小细胞肺癌（NSCLC）患者的临床试验。2021年8月12日，国际知名学术期刊《癌细胞》在线发表了这一成果。

研究人员表示，表皮生长因子受体（EGFR）和血管内皮生长因子（VEGF）途径的双重抑制可能延迟晚期NSCLC的治疗抗性。

研究人员调查了厄洛替尼加贝伐单抗方案对未经治疗的晚期NSCLC患者的疗效和安全性。共有311名患者接受贝伐珠单抗加厄洛替尼（n=157）或只接受厄洛替尼（n=154）。贝伐单抗加厄洛替尼的无进展生存期（PFS）为17.9个月（95%置信区间[CI]，15.2-19.9），仅厄洛替尼为11.2个月（95%CI，9.7-13.8）（比值比[HR]=0.55；95%CI，0.41-0.73；p<0.001）。用贝伐单抗加厄洛替尼治疗的脑转移亚组也显示出PFS的改善（HR=0.48；95%CI，0.27-0.84；p=0.008）。86名（54.8%）和40名（26.1%）患者分别发生了≥3级的治疗相关不良事件。贝伐单抗加厄洛替尼显著改善了未经治疗转移性EGFR突变NSCLC患者的PFS，包括基线时有脑转移的患者。

附：英文原文

Title: Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

Author: Qing Zhou, Chong-Rui Xu, Ying Cheng, Yun-Peng Liu, Gong-Yan Chen, Jiu-Wei Cui, Nong Yang, Yong Song, Xiao-Ling Li, Shun Lu, Jian-Ying Zhou, Zhi-Yong Ma, Shi-Ying Yu, Cheng Huang, Yong-Qian Shu, Zhen Wang, Jin-Ji Yang, Hai-Yan Tu, Wen-Zhao Zhong, Yi-Long Wu

Issue&Volume: 2021-08-12

Abstract: Dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelialgrowth factor (VEGF) pathways may delay therapeutic resistance in advanced non-smallcell lung cancer (NSCLC). This phase 3 study investigated the efficacy and safetyof an erlotinib plus bevacizumab regimen in untreated patients with advanced NSCLC.In total, 311 patients received bevacizumab plus erlotinib (n = 157) or erlotinibonly (n = 154). Progression-free survival (PFS) was 17.9 months (95% confidence interval[CI], 15.2–19.9) for bevacizumab plus erlotinib and 11.2 months (95% CI, 9.7–13.8)for erlotinib only (hazard ratio [HR] = 0.55; 95% CI, 0.41–0.73; p < 0.001). A brainmetastases subgroup treated with bevacizumab plus erlotinib also showed improved PFS(HR = 0.48; 95% CI, 0.27–0.84; p = 0.008). Grade ≥3 treatment-related adverse eventsoccurred in 86 (54.8%) and 40 (26.1%) patients, respectively. Bevacizumab plus erlotinibsignificantly improved PFS in patients with untreated metastatic EGFR-mutated NSCLC, including those with brain metastases at baseline.

DOI: 10.1016/j.ccell.2021.07.005

Source: https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00382-2

Cancer Cell：《癌细胞》，创刊于2002年。隶属于细胞出版社，最新IF：38.585
官方网址：https://www.cell.com/cancer-cell/home
投稿链接：https://www.editorialmanager.com/cancer-cell/default.aspx